Abstract 18084: Coagulopathy and Hospital Outcome in Patients With Covid-19: An Insight From National Inpatient Sample

Abstract

Introduction: SARS-CoV-2 infection has been linked to thrombosis and bleeding. In this study we aim to investigate coagulopathy rates, predictors and in-hospital outcomes in a nationally representative sample of COVID-19 patients. Methods: Using the 2020 National Inpatient Sample. We identified adult patients who were admitted with a principal diagnosis of COVID-19. Mortality difference, LOS, and COC were evaluated as indicators of healthcare resource usage. Regression analysis adjusted for baseline variables and comorbidities compared individuals who developed coagulopathy to those who did not. Logistic regression analysis was used to identify COVID-19 coagulopathy facrtors. p-value <0.05 indicated statistical significance. Results: Among 1,050,045 COVID-19 admissions, 12% (126,225 patients) developed coagulopathy. Those with coagulopathy group had higher rates of in-hospital mortality (aOR 1.31, CI 1.23-1.39, p <0.001), prolonged LOS (aMD 2.29 days, 95% CI 2.12-2.46, p<0.001), and increased COC (aMD 142615$, 95% CI 32905-41299, p<0.001) compared to those that did not develop coagulopathy. Factors associated with coagulopathy included male gender, black race, higher Charleston comorbidity index, and lowest income quartile Conclusion: Approximately 12% of patients developed coagulopathy, which was associated with increased in-hospital mortality, longer length of stay, and higher cost of care. These findings emphasize the importance of identifying and managing coagulation disorders in COVID-19 patients to improve outcomes and allocate healthcare resources effectively. Further research is needed to explore interventions and strategies for mitigating the impact of coagulopathy in this population